Cost of hemophilia A in Turkey: an economic disease burden analysis

References

• Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a Meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546.
   PubMed Web of Science ®Google Scholar
• Zimmerman B, Valentino LA. Hemophilia: in review. Pediatr Rev. 2013;34(7):289–294.
   PubMedGoogle Scholar
• Aledort L, Mannucci PM, Schramm W, et al. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479–486.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Iacobelli M. Progress in the contemporary management of hemophilia: the new issue of patient aging. Eur J Intern Med. 2017;43:16–21.
   PubMed Web of Science ®Google Scholar
• Peters R, Harris T. Advances and innovations in haemophilia treatment. Nat Rev Drug Discov. 2018;17(7):493–508.
   PubMed Web of Science ®Google Scholar
• Guh S, Grosse SD, Mcalister S, et al. Health care expenditures for medicaid-covered males with haemophilia in the United States, 2008. Haemophilia. 2012;18(2):276–283.
   PubMed Web of Science ®Google Scholar
• Tunc O, Kiyak M. Private health insurance in Europe and Turkey. JEFA. 2015;2:409–425.
   Google Scholar
• Turkish Statistical Institute. Health expenditure statistics, 2018.
   Google Scholar
• World Federation of Hemophilia. Report on the annual global survey 2010. Montreal, Quebec, December 2011.
   Google Scholar
• World Federation of Hemophilia. Report on the annual global survey 2011. Montreal, Quebec, December 2012.
   Google Scholar
• World Federation of Hemophilia. Report on the annual global survey 2012. Montreal, Quebec, December 2013.
   Google Scholar
• World Federation of Hemophilia. Report on the annual global survey 2013. Montreal, Quebec, November 2014.
   Google Scholar
• World Federation of Hemophilia. Report on the annual global survey. 2014. Montreal, Quebec, October 2015.
   Google Scholar
• World Federation of Hemophilia. Report on the annual global survey. 2015. Montreal, Quebec, October 2016.
   Google Scholar
• World Federation of Hemophilia. Report on the annual global survey. 2016. Montreal, Quebec, October 2017.
   Google Scholar
• Turkish Statistical Institute. 2018 address-based population registration system results, 2019.
   Google Scholar
• Turkish Statistical Institute. Turkey mid-year population projection. 2013.
   Google Scholar
• Keklik Karadağ F. Evaluation of socio demographic factors and comorbidities in the patiens with hemophilia at Ege Adults Hemophilia Unit [Dissertation]. Ege University, School of Medicine, Internal Medicine Department; 2017.
   Google Scholar
• Karaman K, Akbayram S, Garipardıç M, et al. Diagnostic evaluation of our patients with hemophilia A: 17-year experience. Turk Pediatri Ars. 2015;50(2):96–101.
   PubMedGoogle Scholar
• Çelebi F. Research of morbidity and bleeding areas of hemophilia and von Willebard disease [dissertation]. Ankara: Hacettepe University Medical School; 2016.
   Google Scholar
• Deniz A. Quality of life in pediatric and young adult hemophilia patients with factor level ≤1 [dissertation]. Kocaeli: Kocaeli University; 2017.
   Google Scholar
• Sezgin M. Life quality of children with hemophilia and radiological scores of their arthropathy [dissertation]. Samsun: Ondokuz Mayıs University; 2016.
   Google Scholar
• Demir B. In patients wi̇th hemophilia musculoskeletalinvestigation of changes [dissertation]. Erzurum: Atatürk University, 2014.
   Google Scholar
• ERbaş Yıldız M. Evaluation of the effect of treatment and sedentary lifestyle of haemophiliacs on metabolic condition and renal functions [dissertation]. Istanbul: İstanbul University, Cerrahpaşa Faculty of Medicine; 2011.
   Google Scholar
• Zengin O. The relatıonshıp between frequency and ıntensıty of bleedıng ın hemophılıa patıents and hemophılıc arthropathy, radıologıcal assessment of arthropathy and ıts socıo-economıc ımpacts [dissertation]. Gaziantep: Gaziantep University; 2012.
   Google Scholar
• Turkish Maternal, Child and Adolescent Health Institute. Hemophilia report, 2018.
   Google Scholar
• Kavakli K, Yesilipek A, Antmen B, et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia. 2010;16(3):487–494.
   PubMed Web of Science ®Google Scholar
• Turkish Statistical Institute. Turkey health survey, 2016.
   Google Scholar
• Neyzi O, GüNöz H, Furman A, et al. Türk çocuklarında vücut ağırlığı, boy uzunluğu, baş çevresi ve vücut kitle indeksi referans değerleri. Çocuk Sağlığı ve Hastalıkları Dergisi. 2008;51:1–14.
   Google Scholar
• Zeydanoğlu A. Aynı cerrah tarafından diz artroplastisi yapılan genel anestezi uygulanan hemofili hastalarında kronik ağrı gelişim sıklığının araştırılması [dissertation]. İzmir: Ege University; 2017.
   Google Scholar
• Polat Kelle A. The effectiveness of radiosynovectomy in chronic hemophilic synovitis [dissertation]. Adana: Çukurova University; 2010.
   Google Scholar
• Social Security Institution. Health practice notice, 01 February 2019.
   Google Scholar
• Ministry of Health Turkish Medicines and Medical Devices Agency. Drug price list, 7 Mart 2019.
   Google Scholar
• RxMediaPharma. Version 2019, 19.0.53. Izmir, 7 March 2019.
   Google Scholar
• Turkish Society of Hematology. National guideline for diagnosis and treatment of hemophilia. Ankara: Turkish Society of Hematology; 2017.
   Google Scholar
• Social Security Institution. Statistics annuals, 2017–2019.
   Google Scholar
• Blanchette VS, Key NS, Ljung LR, et al. Subcommittee on factor VIII, factor IX and rare coagulation disorders of the scientific and standardization committee of the international society on thrombosis and hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939.
   PubMed Web of Science ®Google Scholar
• Turkish Society of Hematology. Hemorrhage prevention in adult hemophilia – treatment guideline. Ankara: Turkish Society of Hematology; 2012.
   Google Scholar
• Turkish Society of Hematology. Preparation for surgery in hemophilia – diagnosis and treatment guide. Ankara: Turkish Society of Hematology; 2011.
   Google Scholar
• Cowley P, Bodabilla L, Musgrove P, et al. Content and financing of an essential national package of health services, global assessments in the health sector. Geneva: World Health Organization; 1994.
   Google Scholar
• Neumann PJ, Sanders GD, Russell LB, et al. (Eds). Cost-effectiveness in health and medicine. New York: Oxford University Press; 2016.
   Google Scholar
• Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight european countries. Eur J Health Econ. 2018;19:123–152.
   Google Scholar
• Central Bank of Turkey Exchange Rates 16.07.2018. Available from: https://www.tcmb.gov.tr/kurlar/201807/06072018.xml
   Google Scholar
• Balbay Y, Gagnon-Arpin I, Malhan S, et al. Modeling the burden of cardiovascular disease in Turkey. Anatol J Cardiol 2018;20:235–240.
   PubMed Web of Science ®Google Scholar
• Nerich V, Tissot E, Faradji A, et al. Cost-of-illness study of severe haemophilia a and B in five french haemophilia treatment centres. Pharm World Sci. 2008;30(3):287–292.
   PubMedGoogle Scholar
• Rocha P, Carvalho M, Lopes M, et al. Costs and utilization of treatment in patients with hemophilia. BMC Health Serv Res. 2015;15:484.
   PubMed Web of Science ®Google Scholar
• Café A, Carvalho M, Crato M, et al. Haemophilia A: health and economic burden of a rare disease in Portugal. Orphanet J Rare Dis. 2019;14(1):211.
   PubMed Web of Science ®Google Scholar
• O'Hara J, Hughes D, Camp C, et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106–113.
   PubMed Web of Science ®Google Scholar
• Keshavarz K, Bordbar M, Hashemipoor Z, et al. Economic burden of hemophilia a and B: a case in Iran. Hematology. 2020;25(1):149–155.
   PubMed Web of Science ®Google Scholar
• Cavazza M, Kodra Y, Armeni P, et al. Social/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ. 2016;17(Suppl 1):53–65.
   PubMed Web of Science ®Google Scholar
• Dundar S, Zülfikar B, Kavakli K, et al. A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. J Med Econ. 2005;8(1–4):46–54.
   Google Scholar
• Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus. 2014 Apr;12(Suppl 3):S567–S75.
   PubMed Web of Science ®Google Scholar
• Valentino LA, Pipe SW, Tarantino MD, et al. Healthcare resource utilization among haemophilia a patients in the United States. Haemophilia. 2012;18(3):332–338.
   PubMed Web of Science ®Google Scholar
• Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med. 2017;6(4):46.
   PubMed Web of Science ®Google Scholar
• Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22:s126–33.
   PubMed Web of Science ®Google Scholar
• Rocino A, Cortesi PA, Scalone L, et al. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study)). Haemophilia. 2016;22(1):96–102.
   PubMed Web of Science ®Google Scholar
• Abbonizio F, Giampaolo A, Coppola A, et al. Therapeutic management and costs of severe haemophilia a patients with inhibitors in Italy. Haemophilia. 2014;20(4):e243–e250.
   PubMed Web of Science ®Google Scholar
• Berntorp E, Shapiro AD, White G. Modern haemophilia care. Lancet. 2012;379(9824):1447–1456.
   PubMed Web of Science ®Google Scholar
• Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22(5 Suppl):s126–s133.
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Powell VE, Eldar-Lissai A. Measuring hemophilia caregiver burden: validation of the hemophilia caregiver impact measure. Qual Life Res. 2017;26(9):2551–2562.
   PubMed Web of Science ®Google Scholar
• Lorenzato CS, Santos RB, Fagundes GZZ, et al. Haemophilia experiences, results and opportunities (HERO study) in Brazil: assessment of the psychosocial effects of haemophilia in patients and caregivers. Haemophilia. 2019;25:640–650.
   PubMed Web of Science ®Google Scholar
• Lindvall K, Colstrup L, Loogna K, et al. Knowledge of disease and adherence in adult patients with haemophilia. Haemophilia. 2010;16:592–596.
   PubMed Web of Science ®Google Scholar
• Hoefnagels JW, Fischer K, Bos RAT, et al. A feasibility study on two tailored interventions to improve adherence in adults with haemophilia. Pilot Feasibility Stud. 2020;6(1):189.
   PubMedGoogle Scholar
• Escobar MA, Brewer A, Caviglia H, et al. Recommendations on multidisciplinary management of elective surgery in people with haemophilia. Haemophilia. 2018;24(5):693–702.
   PubMed Web of Science ®Google Scholar
• Gürsoy K. An analysis of public pharmaceutical policy, pricing and spending in Turkey. Journal of Social Security. 2016;6:225–243.
   Google Scholar